{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:41:31Z","timestamp":1789656091067,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-1-2182"],"award-info":[{"award-number":["2024-1-2182"]}]},{"name":"Beijing high-level Public Health Technical Talent Construction Project","award":["03-23"],"award-info":[{"award-number":["03-23"]}]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","award":["SYLH2023-04"],"award-info":[{"award-number":["SYLH2023-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12042-7","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:14:40Z","timestamp":1766150080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interferon therapy-induced reduction in PD-1\u2009+\u2009CD8\u2009+\u2009and CD160\u2009+\u2009CD8\u2009+\u2009T cells is associated with functional cure in hepatitis B"],"prefix":"10.1186","volume":"25","author":[{"given":"Daqiong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianru","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"4","key":"12042_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1473-3099(22)00743-5","volume":"23","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Nguyen MH. Curing chronic hepatitis B virus infection. Lancet Infect Dis. 2023;23(4):392\u20133.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"12042_CR2","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","volume":"63","author":"J Liu","year":"2014","unstructured":"Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014;63(10):1648\u201357.","journal-title":"Gut"},{"issue":"1","key":"12042_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12985-024-02512-w","volume":"21","author":"Y Li","year":"2024","unstructured":"Li Y, Yang S, Li C, Ma Z, Zhang M, Zou W, et al. Efficacy of short-term Peg-IFN \u03b1-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study. Virol J. 2024;21(1):231.","journal-title":"Virol J"},{"key":"12042_CR4","doi-asserted-by":"crossref","unstructured":"Islam M, Kumar K, Sevak JK, Jindal A, Vyas AK, Ramakrishna G, et al. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. Hepatol Commun. 2023;7(5).","DOI":"10.1097\/HC9.0000000000000098"},{"key":"12042_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms21197357","volume":"21","author":"DJ Verdon","year":"2020","unstructured":"Verdon DJ, Mulazzani M, Jenkins MR. Cellular and molecular mechanisms of CD8(+) T cell Differentiation, dysfunction and exhaustion. Int J Mol Sci. 2020;21:19.","journal-title":"Int J Mol Sci"},{"key":"12042_CR6","doi-asserted-by":"crossref","unstructured":"Zhou D, Liu L, Liu J, Li H, Zhang J, Cao Z. A systematic review of the advances in the study of T lymphocyte suppressor receptors in HBV infection: potential therapeutic targets. J Clin Med. 2024;13(5).","DOI":"10.3390\/jcm13051210"},{"issue":"1","key":"12042_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen LT, Ohashi PS. Clinical Blockade of PD1 and LAG3\u2013potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45\u201356.","journal-title":"Nat Rev Immunol"},{"key":"12042_CR8","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.3389\/fimmu.2019.02240","volume":"10","author":"K Heim","year":"2019","unstructured":"Heim K, Neumann-Haefelin C, Thimme R, Hofmann M. Heterogeneity of HBV-Specific CD8(+) T-Cell failure: implications for immunotherapy. Front Immunol. 2019;10:2240.","journal-title":"Front Immunol"},{"issue":"3","key":"12042_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2015.10.013","volume":"64","author":"A de Niet","year":"2016","unstructured":"de Niet A, Stelma F, Jansen L, Sinnige MJ, Remmerswaal EB, Takkenberg RB, et al. Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy. J Hepatol. 2016;64(3):539\u201346.","journal-title":"J Hepatol"},{"issue":"1","key":"12042_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12109","volume":"255","author":"TJ Braciale","year":"2013","unstructured":"Braciale TJ, Hahn YS. Immunity to viruses. Immunol Rev. 2013;255(1):5\u201312.","journal-title":"Immunol Rev"},{"issue":"1","key":"12042_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/HEP.0000000000000524","volume":"79","author":"P Jiang","year":"2024","unstructured":"Jiang P, Jia H, Qian X, Tang T, Han Y, Zhang Z, et al. Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-\u03b1 in patients with chronic hepatitis B. Hepatology. 2024;79(1):167\u201382.","journal-title":"Hepatology"},{"issue":"2","key":"12042_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","volume":"73","author":"I Tout","year":"2020","unstructured":"Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73(2):409\u201322.","journal-title":"J Hepatol"},{"key":"12042_CR13","doi-asserted-by":"crossref","unstructured":"Moini M, Fung S. HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure. Viruses. 2022;14(4).","DOI":"10.3390\/v14040657"},{"key":"12042_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coi.2015.06.016","volume":"36","author":"LG Guidotti","year":"2015","unstructured":"Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol. 2015;36:61\u20136.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"12042_CR15","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/hep.27586","volume":"61","author":"WP Brouwer","year":"2015","unstructured":"Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding pegylated interferon to Entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology. 2015;61(5):1512\u201322.","journal-title":"Hepatology"},{"issue":"7","key":"12042_CR16","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/infdis\/jix024","volume":"215","author":"H Chi","year":"2017","unstructured":"Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, et al. Pegylated interferon Alfa-2b Add-on treatment in hepatitis B virus envelope Antigen-Positive chronic hepatitis B patients treated with Nucleos(t)ide analogue: A Randomized, controlled trial (PEGON). J Infect Dis. 2017;215(7):1085\u201393.","journal-title":"J Infect Dis"},{"key":"12042_CR17","unstructured":"EASL Clinical Practice. Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025."},{"issue":"2","key":"12042_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","volume":"159","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Gill US, Hong M, Kunasegaran K, Tan DZM, Ahmad R, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection. Gastroenterology. 2020;159(2):652\u201364.","journal-title":"Gastroenterology"},{"issue":"1","key":"12042_CR19","doi-asserted-by":"publisher","first-page":"2339944","DOI":"10.1080\/22221751.2024.2339944","volume":"13","author":"J Wang","year":"2024","unstructured":"Wang J, Zhu L, Zhang S, Zhang Z, Fan T, Cao F, et al. Clinical outcomes of treatment-na\u00efve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA. Emerg Microbes Infect. 2024;13(1):2339944.","journal-title":"Emerg Microbes Infect"},{"issue":"10","key":"12042_CR20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1136\/gutjnl-2024-332182","volume":"73","author":"R Fan","year":"2024","unstructured":"Fan R, Zhao S, Niu J, Ma H, Xie Q, Yang S, et al. High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy. Gut. 2024;73(10):1725\u201336.","journal-title":"Gut"},{"issue":"1","key":"12042_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/apt.16149","volume":"53","author":"SG Lim","year":"2021","unstructured":"Lim SG, Phyo WW, Ling JZJ, Cloherty G, Butler EK, Kuhns MC, et al. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). Aliment Pharmacol Ther. 2021;53(1):172\u201382.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"12042_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jvh.13151","volume":"26","author":"MH Li","year":"2019","unstructured":"Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat. 2019;26(Suppl 1):32\u201341.","journal-title":"J Viral Hepat"},{"issue":"1","key":"12042_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","volume":"77","author":"D Huang","year":"2022","unstructured":"Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42\u201354.","journal-title":"J Hepatol"},{"key":"12042_CR24","doi-asserted-by":"publisher","first-page":"1120300","DOI":"10.3389\/fcimb.2023.1120300","volume":"13","author":"Y Guo","year":"2023","unstructured":"Guo Y, Han J, Zhang Y, Jin C, Zhang Y, He J, et al. End-of-treatment anti-HBs levels and hbeag status identify durability of HBsAg loss after PEG-IFN discontinuation. Front Cell Infect Microbiol. 2023;13:1120300.","journal-title":"Front Cell Infect Microbiol"},{"key":"12042_CR25","doi-asserted-by":"crossref","unstructured":"Rica R, Waldherr M, Miyakoda E, Kutschat AP, Sch\u00fclein M, Zhang J et al. HDAC1 controls the generation and maintenance of effector-like CD8\u2009+\u2009T cells during chronic viral infection. J Exp Med. 2025;222(8).","DOI":"10.1084\/jem.20240829"},{"key":"12042_CR26","doi-asserted-by":"crossref","unstructured":"Han JW, Shin EC. Liver-resident memory CD8(+) T cells: possible roles in chronic HBV infection. Int J Mol Sci. 2020;22(1).","DOI":"10.3390\/ijms22010283"},{"key":"12042_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/1743-422X-9-274","volume":"9","author":"YZ Liu","year":"2012","unstructured":"Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ. Pegylated interferon \u03b1 enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients. Virol J. 2012;9:274.","journal-title":"Virol J"},{"issue":"20","key":"12042_CR28","first-page":"4675","volume":"21","author":"XJ Ma","year":"2017","unstructured":"Ma XJ, Chen XF, Chen WL, Chen R, Huang J, Luo XD, et al. Study on the distribution of CD8\u2009+\u2009memory T cell subsets and IFN-\u03b3 level during the spontaneous clearance of hepatitis B virus in patients with chronic hepatitis B virus infection. Eur Rev Med Pharmacol Sci. 2017;21(20):4675\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"12042_CR29","doi-asserted-by":"publisher","first-page":"143026","DOI":"10.1155\/2010\/143026","volume":"2010","author":"Y Jiang","year":"2010","unstructured":"Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with Adefovir dipivoxil. Mediators Inflamm. 2010;2010:143026.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"12042_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12016-014-8465-4","volume":"50","author":"X Li","year":"2016","unstructured":"Li X, Liu X, Tian L, Chen Y. Cytokine-Mediated Immunopathogenesis of hepatitis B virus infections. Clin Rev Allergy Immunol. 2016;50(1):41\u201354.","journal-title":"Clin Rev Allergy Immunol"},{"key":"12042_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C. Cytokine regulation and function in T cells. Annu Rev Immunol. 2021;39:51\u201376.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"12042_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10875-009-9328-2","volume":"30","author":"J Ge","year":"2010","unstructured":"Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol. 2010;30(1):60\u20137.","journal-title":"J Clin Immunol"},{"issue":"3","key":"12042_CR33","doi-asserted-by":"publisher","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","volume":"6","author":"B Ye","year":"2015","unstructured":"Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015;6(3):e1694.","journal-title":"Cell Death Dis"},{"issue":"10","key":"12042_CR34","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/gutjnl-2024-332290","volume":"73","author":"A Vecchi","year":"2024","unstructured":"Vecchi A, Rossi M, Tiezzi C, Fisicaro P, Doselli S, Gabor EA, et al. HBcrAg values May predict virological and immunological responses to pegIFN-\u03b1 in NUC-suppressed HBeAg-negative chronic hepatitis B. Gut. 2024;73(10):1737\u201348.","journal-title":"Gut"},{"issue":"11","key":"12042_CR35","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2022-327202","volume":"72","author":"M Rossi","year":"2023","unstructured":"Rossi M, Vecchi A, Tiezzi C, Barili V, Fisicaro P, Penna A, et al. Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro. Gut. 2023;72(11):2123\u201337.","journal-title":"Gut"},{"key":"12042_CR36","doi-asserted-by":"crossref","unstructured":"Ren S, Lin X, Wang W, Xiaoxiao W, Ma L, Zheng Y, et al. A greater frequency of Circulating CCR7loPD-1hi follicular helper T cells indicates a durable clinical cure after Peg IFN-\u03b1 therapy in chronic hepatitis B patients. Hepatol Commun. 2025;9(5).","DOI":"10.1097\/HC9.0000000000000690"},{"issue":"3","key":"12042_CR37","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","volume":"150","author":"JJ Park","year":"2016","unstructured":"Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, et al. Hepatitis B Virus\u2013Specific and global T-Cell dysfunction in chronic hepatitis B. Gastroenterology. 2016;150(3):684\u2013e955.","journal-title":"Gastroenterology"},{"issue":"5","key":"12042_CR38","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/eji.201141852","volume":"42","author":"W Wu","year":"2012","unstructured":"Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y, et al. Blockade of Tim-3 signaling restores the virus-specific CD8\u207a T-cell response in patients with chronic hepatitis B. Eur J Immunol. 2012;42(5):1180\u201391.","journal-title":"Eur J Immunol"},{"key":"12042_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"12042_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/1744666X.2023.2198209","volume":"19","author":"E Allahmoradi","year":"2023","unstructured":"Allahmoradi E, Mohammadi R, Kheirandish Zarandi P, Alavian SM, Heiat M. The CD8\u2009+\u2009T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review. Expert Rev Clin Immunol. 2023;19(6):671\u201388.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"12042_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2013.10.022","volume":"146","author":"DC Kroy","year":"2014","unstructured":"Kroy DC, Ciuffreda D, Cooperrider JH, Tomlinson M, Hauck GD, Aneja J, et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology. 2014;146(2):550\u201361.","journal-title":"Gastroenterology"},{"issue":"4","key":"12042_CR42","doi-asserted-by":"publisher","first-page":"e0167022","DOI":"10.1128\/jvi.01670-22","volume":"97","author":"C Mallarino-Haeger","year":"2023","unstructured":"Mallarino-Haeger C, Pino M, Viox EG, Pagliuzza A, King CT, Nguyen K, et al. HIV-1 DNA and immune activation levels differ for Long-Lived T-Cells in lymph Nodes, compared with peripheral Blood, during antiretroviral therapy. J Virol. 2023;97(4):e0167022.","journal-title":"J Virol"},{"key":"12042_CR43","doi-asserted-by":"crossref","unstructured":"Gao P, Luo Y, Chen L, Yang Z, He Q, Li J. The effect of hepatitis B virus on T lymphocyte and its subsets in chronic hepatitis B patients in different ALT stages: a new concept ALT in HBV infection. Int Immunopharmacol. 2021;101(Pt A):108182.","DOI":"10.1016\/j.intimp.2021.108182"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12042-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:14:41Z","timestamp":1766150081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12042-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12042"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12042-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent at the time of enrollment, which included permission for storage and future research use of PBMC samples. The protocol and consent form for the study were approved by the research ethics committee of the Beijing You\u2019an Hospital, Capital Medical University, China ([2016]16), and conform to the principles of CFDA\/GCP and Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors were informed and consented to the publication of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1728"}}